Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology · 2024
DOI: 10.1016/j.jacc.2024.09.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American College of Cardiology, 2024. Verfasst von Martin S Maron und 34 weiteren Autor:innen. Beteiligte Einrichtung: Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. Electronic address: martin.maron@lahey.org. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cytokinetics Inc.
Abstract (Originalsprache)
BACKGROUND: Aficamten is a cardiac myosin inhibitor that mitigates left ventricular outflow gradients in obstructive hypertrophic cardiomyopathy (oHCM). The clinical efficacy of aficamten across multiple outcome domains in oHCM has not been fully defined. OBJECTIVES: This responder analysis from the SEQUOIA-HCM (Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM) trial characterizes the clinical impact of aficamten. METHODS: Patients who were symptomatic of oHCM were randomized to aficamten (n = 142) or placebo (n = 140) daily for 24 weeks. Outcomes assessed included the proportion of patients with complete hemodynamic response (rest and Valsalva gradient
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lahey Hospital and Medical Center, Burlington, Massachusetts, USA. Electronic address: martin.maron@lahey.org.
- Oregon Health and Science University, Portland, Oregon, USA.
- University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute Kansas City, Kansas City, Missouri, USA.
- Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII, A Coruña, Spain.
- University of California, San Francisco, San Francisco, California, USA.
- Chaim Sheba Medical Center, Ramat-Gan and Tel Aviv University, Israel.
Förderung
- Cytokinetics Inc
Zitieren
APA
Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Abraham, T. P., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H. D., Garcia-Pavia, P., Hagège, A. A., Januzzi, J. L., Kulac, I., Lee, M. M. Y., Lewis, G. D., Ma, C. S., Michels, M., …, & SEQUOIA-HCM Investigators (2024). Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2024.09.003
Vancouver
Maron MS, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Arad M, et al. Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology. 2024. doi:10.1016/j.jacc.2024.09.003
BibTeX
@article{Maron2024,
author = {Maron, Martin S and Masri, Ahmad and Nassif, Michael E and Barriales-Villa, Roberto and Abraham, Theodore P and Arad, Michael and Cardim, Nuno and Choudhury, Lubna and Claggett, Brian and Coats, Caroline J and Düngen, Hans-Dirk and Garcia-Pavia, Pablo and Hagège, Albert A and Januzzi, James L and Kulac, Ian and Lee, Matthew M Y and Lewis, Gregory D and Ma, Chang-Sheng and Michels, Michelle and Oreziak, Artur and Owens, Anjali T and Spertus, John A and Solomon, Scott D and Tfelt-Hansen, Jacob and van Sinttruije, Marion and Veselka, Josef and Watkins, Hugh C and Jacoby, Daniel L and Heitner, Stephen B and Kupfer, Stuart and Malik, Fady I and Meng, Lisa and Wohltman, Amy and Olivotto, Iacopo and SEQUOIA-HCM Investigators, SEQUOIA-HCM Investigators},
title = {Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy},
journal = {Journal of the American College of Cardiology},
year = {2024},
doi = {10.1016/j.jacc.2024.09.003}
}
EUVIMED